Biologics switch in psoriasis.
Immunotherapy
; 11(6): 531-541, 2019 04.
Article
en En
| MEDLINE
| ID: mdl-31135243
ABSTRACT
Aim:
No guidelines exist for biologic switch in psoriasis after treatment failure. Although, switching between TNF-α antagonists has been reviewed, switching information about newer biologics is limited. Materials &methods:
We did a thorough systematic review from 'PubMed' and 'Embase', which includes new biologics such as IL-12/IL-23 antagonists, IL-17A antagonists and IL-23 antagonists. Results &conclusion:
New biologics such as IL-17 antagonist or IL-23 antagonist show greater responses in bio-experienced patients and could even be used for patients in whom previous treatments failed.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Productos Biológicos
/
Antiinflamatorios
Tipo de estudio:
Guideline
/
Systematic_reviews
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Immunotherapy
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Año:
2019
Tipo del documento:
Article
País de afiliación:
Taiwán